A. Whelton

R. Stout, A. Whelton, A. Watson, 1987, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Antibiotic pharmacokinetics and clinical application in renal insufficiency.

A. Whelton, Andrew Whelton, 1982, The Medical clinics of North America.

Studies of marked and persistent sodium retention in previously fasted and sodium-deprived obese subjects.

W. G. Walker, A. Whelton, C. R. Cook, 1987, Metabolism: clinical and experimental.

Once‐Daily Lisinopril Compared with Twice‐Daily Captopril in the Treatment of Mild to Moderate Hypertension: Assessment of Office and Ambulatory Blood Pressures

O. Tresznewsky, A. Whelton, B. Dunne, 1990, Journal of clinical pharmacology.

Aminoglycoside nephrotoxicity--a tale of two transports.

K. Solez, A. Whelton, Andrew Whelton, 1982, The Journal of laboratory and clinical medicine.

Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate.

M. Hall-Craggs, K. Solez, W. Bender, 1984, The American journal of medicine.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

A. Whelton, T. Burke, S. Henderson, 2002, The American journal of managed care.

COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.

A. Whelton, 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.

J. Kostis, O. Tresznewsky, A. Whelton, 1992, Journal of human hypertension.

Tricenter Assessment of the Efficacy of the ACE Inhibitor, Moexipril, by Ambulatory Blood Pressure Monitoring

W. White, A. Whelton, M. Stimpel, 1995, Journal of clinical pharmacology.

Pathophysiologic Mechanisms in Aminoglycoside Nephrotoxicity

K. Solez, A. Whelton, 1983, Journal of clinical pharmacology.

Therapeutic implications of gentamicin accumulation in severly diseased kidneys.

W. G. Walker, A. Whelton, L. Fox, 1976, Archives of internal medicine.

Ambulatory Blood Pressure Monitoring: A New Window to Clinical Therapeutic Decisions in Hypertension

O. Tresznewsky, A. Whelton, 1990, Journal of clinical pharmacology.

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial

P. Gorelick, W. White, J. Borer, 2022, Arthritis & Rheumatology (Hoboken, N.j.).

Clinical Therapeutic Conference

J. Somberg, A. Whelton, A. Laddu, 1992, American journal of therapeutics.

Mechanisms of lysine-induced acute renal failure in rats.

L. Racusen, K. Solez, A. Whelton, 1985, Kidney international.

Nephrotoxicity of lysine and of a single dose of aminoglycoside in rats given lysine.

L. Racusen, K. Solez, A. Whelton, 1984, The Journal of laboratory and clinical medicine.

Carbenicillin concentrations in normal and diseased kidneys. A therapeutic consideration.

W. G. Walker, A. Whelton, L. A. Porteous, 1973, Annals of internal medicine.

A. Whelton, 2000, American journal of therapeutics.

Therapeutic Manipulations in Uremic Bleeding

A. Whelton, A. Watson, 1985, Journal of clinical pharmacology.

Long‐Term Bumetanide Treatment of Renal Edema. Comparison with Furosemide

A. Whelton, 1981, Journal of clinical pharmacology.

Andrew Whelton Hyperuricemia and Hypertension : A Confluence of Concepts

A. Whelton, 2022 .

Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate

R. Thadhani, A. Vergani, A. Whelton, 2018, Nephron.

Comparison of the intrarenal disposition of tobramycin and gentamicin: therapeutic and toxicologic answers.

W. G. Walker, A. Whelton, G. Carter, 1978, Journal of Antimicrobial Chemotherapy.

Hyperuricemia and hypertension: a confluence of concepts.

A. Whelton, 2012, Hypertension.

Intrarenal antibiotic distribution in health and disease

W. G. Walker, A. Whelton, 1974 .

TREATMENT OF METABOLIC ALKALOSIS

A. Whelton, R. Pain, L. Worthley, 1974 .

ATHEROEMBOLIC RENAL DISEASE

J. Vassalotti, A. Whelton, F. Delgado, 1996, American journal of therapeutics.

Clinical Therapeutic Conference

J. Somberg, A. Whelton, H. Gómez, 1991 .

Post-traumatic acute renal failure in Vietnam. A comparison with the Korean war experience.

A. Whelton, J. V. Donadiq, 1969, The Johns Hopkins medical journal.

Selective inhibition of thromboxane synthesis in glycerol-induced acute renal failure.

K. Solez, R. Stout, N. Adkinson, 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hypertension and renal dysfunction in bone marrow transplant recipients.

A. Whelton, R. Saral, B. Kone, 1988, The Quarterly journal of medicine.

Renal blood flow, glomerular filtration rate, and renal morphology in cyclosporine-induced acute renal failure in Munich-Wistar rats.

L. Racusen, K. Solez, A. Whelton, 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Andreas Hoeft, A. Hoeft, N. Nussmeier, 2005, The New England journal of medicine.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

R. Makuch, T. Pincus, L. Simon, 2000, JAMA.

Non-steroidal anti-inflammatory drugs

T. Stürmer, A. Whelton, G. Porter, 2003 .

Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.

A. Whelton, C. Wentworth, T. Burke, 2002, Clinical therapeutics.

A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

S. Z. Zhao, M. Reynolds, A. Whelton, 2001, Clinical therapeutics.

Cyclooxygenase-2–Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

A. Whelton, J. Puma, K. Verburg, 2001, American journal of therapeutics.

Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors.

A. Whelton, Andrew Whelton, 2001, The American journal of medicine.

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.

A. Whelton, 1999, The American journal of medicine.

An approach to the interpretation of drug concentrations in the kidney.

W. G. Walker, A. Whelton, 1978, The Johns Hopkins medical journal.

Intrarenal distribution of penicillin, cephalothin, ampicillin and oxytetracycline during varied states of hydration.

W. G. Walker, D. Sapir, A. Whelton, 1971, The Journal of pharmacology and experimental therapeutics.

Acyclovir kinetics in end‐stage renal disease

J. Longstreth, O. Laskin, R. Keeney, 1982, Clinical pharmacology and therapeutics.

Treatment of Gram‐Negative Infections in Patients with Renal Impairment: New Alternatives to Aminoglycosides

A. Whelton, 1988, Journal of clinical pharmacology.

Intrarenal distribution of ampicillin in the normal and diseased human kidney.

W. G. Walker, D. Sapir, A. Whelton, 1972, The Journal of infectious diseases.

Quinine therapy and peritoneal dialysis in acute renal failure complicating malarial haemoglobinuria.

A. Whelton, L. Kazyak, J. Donadio, 1968, Lancet.

Infectious diseases and antimicrobial agents

H. Neu, J. Williams, A. Whelton, 1981 .

Cure of cryptococcemia and preservation of graft function in a renal transplant recipient.

A. Whelton, A. Watson, R. Russell, 1984, Archives of internal medicine.

Effect of renal failure on the pharmacokinetics of acyclovir.

J. Longstreth, O. Laskin, R. Keeney, 1982, The American journal of medicine.

Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure.

S. Liao, O. Laskin, P. Lietman, 1982, The American journal of medicine.

Doxycycline pharmacokinetics in the absence of renal function.

W. G. Walker, A. Whelton, T. Twomey, 1974, Kidney international.

Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma.

A. Whelton, 1978, Bulletin of the New York Academy of Medicine.

Pharmacokinetic characteristics of doxycycline accumulation in normal and severely diseased kidneys.

W. G. Walker, A. Whelton, S. Nightingale, 1975, The Journal of infectious diseases.

Neomycin toxicity revisited.

P. Whelton, H. Masur, A. Whelton, 1976, Archives of surgery.

Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors

W. White, J. Lefkowith, J. Kent, 2002, Hypertension.

The aminoglycosides.

A. Whelton, 1984, Clinical orthopaedics and related research.

Acute renal failure complicating rickettsial infections in glucose-6-phosphate dehydrogenase-deficient individuals.

A. Whelton, B. Elisberg, J. Donadio, 1968, Annals of internal medicine.

Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison.

D. Klassen, R. Stout, A. Whelton, 1990, Annals of internal medicine.

Renal Effects of Over‐the‐Counter Analgesics

A. Whelton, 1995, Journal of clinical pharmacology.

Current and Future Therapeutic Options for the Management of Gout

A. Whelton, 2010, American journal of therapeutics.

The intrarenal distribution of aztreonam in healthy and diseased kidneys: clinical therapeutic implications.

R. Stout, A. Whelton, A. Watson, 1984, The Journal of infectious diseases.

The Pathology of Acute Renal Failure Due to Interstitial Nephritis in Man with Comments on the Role of Interstitial Inflammation and Sex in Gentamicin Nephrotoxicity

A. Whelton, J. Sraer, OLIVIER KOURILSKY, 1982, Medicine.

ACUTE RENAL PAPILLARY NECROSIS INDUCED BY IBUPROFEN

A. Whelton, M. Atta, Mohamed G. Atta, 1997, American journal of therapeutics.

The position of paracetamol in the world of analgesics.

R. Day, G. Graham, A. Whelton, 2000, American journal of therapeutics.

Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery

N. Nussmeier, G. Joshi, N. Singla, 2006, Anesthesiology.

Editorial: Intrarenal antibiotic distribution in health and disease.

W. G. Walker, A. Whelton, 1974, Kidney International.

Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

M. Schiff, A. Whelton, 2000, Seminars in arthritis and rheumatism.

Post-traumatic acute renal failure.

A. Whelton, 1979, Bulletin of the New York Academy of Medicine.

Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis

V. Strand, W. White, A. Whelton, 2004, American journal of therapeutics.

Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat.

L. Racusen, K. Solez, A. Whelton, 1986, Clinical nephrology.

Syndrome of perceptive deafness and renal tubular acidosis

W. G. Walker, A. Whelton, F. L. Ozer, 1974 .

Effects of celecoxib and naproxen on renal function in the elderly.

P. Isakson, A. Whelton, K. Verburg, 2000, Archives of internal medicine.

A STUDY DESIGN FOR COMPARING THE EFFECTS OF MISSING DAILY DOSES OF ANTIHYPERTENSIVE DRUGS

Brian F. Johnson, A. Whelton, 1994, American journal of therapeutics.

Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study

B. Hunt, L. Gunawardhana, A. Whelton, 2017, Journal of the American Heart Association.

Minimizing Cardiovascular Complications During the Treatment of Osteoarthritis

A. Gibofsky, A. Whelton, 2011, American journal of therapeutics.

The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo‐controlled, double‐blind, crossover trial

S. Lai, M. Schär, R. Weiss, 2018, American heart journal.

Metastatic pulmonary calcification in the renal transplant recipient.

A. Whelton, P. Terry, J. Nissim, 1980, The American review of respiratory disease.

Appropriate Analgesia: An Evidence-based Evaluation of the Role of Acetaminophen in Pain Management

A. Whelton, 2005 .

Sustained Antihypertensive Activity of Diltiazem SR: Double‐Blind, Placebo‐Controlled Study with 24‐Hour Ambulatory Blood Pressure Monitoring

J. Eff, A. Whelton, D. Magner, 1992, Journal of clinical pharmacology.

Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus

B. Pitt, W. White, J. Sowers, 2003 .

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

W. White, A. Whelton, J. Puma, 2002, The American journal of cardiology.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Thomas Brabant, Bertram Pitt, B. Pitt, 2005, Archives of internal medicine.

Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay

R. Riddell, M. Konstam, K. Horgan, 2009 .

Trioza vitreoradiata (Maskell) (Homoptera: Psylloidea), a New Zealand species new to Ireland.

A. Whelton, J. .. O'connor, R. Dunne, 2004 .

Controversies in COX-2 selective inhibition.

C. Bombardier, M. Dougados, M. Hochberg, 2002, The Journal of rheumatology.

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study

K. Saag, B. Hunt, L. Gunawardhana, 2018, Arthritis & rheumatology.

Renal Function in Gout: Long-Term Treatment Effects of Febuxostat

Lin Zhao, P. Macdonald, B. Hunt, 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

K. Saag, B. Hunt, L. Gunawardhana, 2018, Arthritis Research & Therapy.

Time-trends in gastroprotection with NSAIDs

T. Schnitzer, S. Gabriel, J. Lei, 2010 .

OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus

B. Pitt, W. White, J. Sowers, 2003 .

Dibekacin Intrarenal Distribution Characteristics and Renal Cortical Elution Kinetics. Comparison with Gentamicin and Tobramycin

R. Stout, A. Whelton, G. Carter, 1980, Journal of clinical pharmacology.

Post-traumatic acute renal failure in Vietnam: A milestone in progress.

A. Whelton, 1974, Connecticut medicine.

Carbenicillin-induced acidosis and seizures.

W. G. Walker, A. Whelton, M. O. Darwish, 1971, JAMA.

Concepts and Clinical Considerations in Drug‐Induced Nephrotoxicity. Comments on a Review Symposium

A. Whelton, 1983, Journal of clinical pharmacology.

Prevention of Contrast Media-Induced Renal Dysfunction With Prostaglandin E 1 : A Randomized, Double-Blind, Placebo-Controlled Study

J. Brinker, P. Bernink, J. Koch, 2001, American journal of therapeutics.

Calcium Channel Blockade in Experimental Aminoglycoside Nephrotoxicity

D. Klassen, R. Stout, A. Whelton, 1987, Journal of clinical pharmacology.

Sulindac and renal impairment.

M. Hall-Craggs, K. Solez, W. Bender, 1983, JAMA.

Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.

A. Whelton, C. West, K. Verburg, 2006, Kidney international.

Antibacterial chemotherapy in renal insufficiency. A review.

A. Whelton, 1974, Antibiotics and Chemotherapy.

Therapeutic Considerations in the Use of Antibiotics in Renal Insufficiency

A. Whelton, 1980, Obstetrics and Gynecology.

Therapeutic Implications of Doxycycline and Cephalothin Concentrations in the Female Genital Tract

T. Craig, T. M. King, A. Whelton, 1980, Obstetrics and Gynecology.

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.

A. Whelton, K. Verburg, G. Geis, 2000, American journal of therapeutics.

The Novel Therapeutic Implications of Azlocillin's Dose‐Dependent Pharmacokinetics: Contributing Physiologic Mechanisms and a Prospective, Cross‐Over Designed Trial

R. Stout, A. Whelton, A. Watson, 1987, Journal of clinical pharmacology.

Thromboembolic Cardiovascular Risk Among Arthritis Patients Using Cyclooxygenase-2-Selective Inhibitor or Nonselective Cyclooxygenase Inhibitor Nonsteroidal Anti-inflammatory Drugs

M. Reeves, A. Whelton, W. Spalding, 2007, American journal of therapeutics.

Complications of the Cox-II inhibitors parecoxib and valdecoxib after cardiac surgery

N. Nussmeier, A. Whelton, Mark T. Brown, 2005 .

SAT0094 Celecoxib does not increase the risk of cardiac failure, oedema, or hypertension compared to nsaids: results from success 1, a double blind, randomised trial in 13,274 oa patients

W. White, A. Whelton, G. Singh, 2001 .

Intrarenal gentamicin concentrations in health and disease. Therapeutic and nephrotoxic implications

W. G. Walker, A. Whelton, G. Carter, 1975 .

Effects of lysine and other amino acids on kidney structure and function in the rat.

L. Racusen, K. Solez, A. Whelton, 1985, The American journal of pathology.

The cyclooxygenase-2 specific inhibitor valdecoxib is not associated with an increased risk of cardiovascular thrombotic events in arthritis patients

W. White, A. Whelton, K. Verburg, 2003 .

Potassium in cardiovascular and renal medicine : arrhythmias, myocardial infarction, and hypertension

P. Whelton, W. G. Walker, A. Whelton, 1986 .

Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

A. Whelton, T. Burke, S. Henderson, 2002, American Journal of Managed Care.

The Evaluation of the Diuretic Action of Parenteral Formulations of Metolazone

J. Molnar, J. Somberg, V. Ranade, 2007, American journal of therapeutics.

Cure of cryptococcal infection during continued immunosuppressive therapy.

A. Whelton, A. Watson, Russell Rp, 1985, The Quarterly journal of medicine.

Acute renal failure : correlations between morphology and function

K. Solez, A. Whelton, 1984 .

Acute toxic drug ingestions at the Johns Hopkins Hospital. 1963 through 1970.

W. G. Walker, A. Whelton, D. Snyder, 1973, The Johns Hopkins medical journal.

Ambulatory blood pressure monitoring: A new window to decision‐making in hypertension

A. Whelton, 1992, Clinical cardiology.

Hyperuricemia and hypertension: a confluence of concepts.

A. Whelton, 2012, Hypertension.

Reflections on use of the renal biopsy as the "gold standard" in distinguishing transplant rejection from cyclosporine nephrotoxicity.

L. Racusen, K. Solez, J. Burdick, 1985, Transplantation proceedings.